Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-962212 · 1 trial · 1 indication
measured by incidence
measured by incidence
measured by incidence
measured by incidence
measured by incidence
measured by incidence
measured by incidence
measured by ECG
measured by ECG
measured by ECG
measured by telemetry
measured by iohexol administration plasma clearance and the Chronic Kidney Disease-Epidemiology Collaborative Group (CKD EPI) equation
measured by serum biomarkers
measured by urine biomarkers
measured by urine biomarkers
| Arm | Type | Description |
|---|---|---|
| BMS-962212 Two Hour Administration | EXPERIMENTAL | Intravenous administered over 2 hours of BMS-962212 |
| BMS-962212 5 Day Administration | EXPERIMENTAL | Intravenous administered over 5 days of BMS-962212 |
| BMS-962212 and Aspirin | EXPERIMENTAL | BMS-962212 intravenous administration, followed by aspirin oral administration, then combination administration of BMS-962212 and aspirin |
| Placebo and Aspirin | PLACEBO_COMPARATOR | Placebo intravenous administration, followed by aspirin, then combination administration of placebo and aspirin |
| Placebo | PLACEBO_COMPARATOR | Placebo intravenous administration |
| Name | Type | Description |
|---|---|---|
| BMS-962212 | DRUG | Intravenous Infusion administration over 2 hours or 5 days |
| Aspirin | DRUG | Oral administration |
| Placebo | OTHER | Oral administration |
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECG, and clinical laboratory dete...
BMS-962212 is an investigational small molecule being developed by Bristol-Myers Squibb for the treatment of thrombosis, a condition involving blood clot formation. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
The specific molecular target of BMS-962212 is not disclosed in available information. It is a small molecule being studied for its effects on thrombosis, but its precise mechanism of action has not been publicly detailed.
BMS-962212 is being developed by Bristol-Myers Squibb Company, a global biopharmaceutical company. The company is listed on the New York Stock Exchange under the ticker symbol BMY.
BMS-962212 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies and is still undergoing clinical trials to evaluate its safety and efficacy.
BMS-962212 has one completed Phase 1 clinical trial, identified as NCT03197779. This study evaluated the safety, pharmacokinetics, and pharmacodynamics of short and long intravenous infusions of BMS-962212 in healthy subjects in the United States.
No alternative names for BMS-962212 have been identified. It is referred to solely by its developmental code name, BMS-962212, in clinical trial registries and available scientific literature.